Multiple receptors for dopamine

Kainic acid lesions of striatum and decortication reduce specific [3H]sulpiride binding in rats, so D-2 receptors exist post-synaptically on corticostriate afferents and striatal neurons

Unilateral kainic acid lesions of rat striatum reduced specific striatal [3H]spiperone and [3H]sulpiride binding sites (Bmax) by 52 and 67% respectively compared with the intact side. The dissociation constant (KD) for [3H]spiperone binding was unchanged but that for [3H]sulpiride binding was reduced. Specific striatal [3H]spiperone and [3H]sulpiride binding was reduced by 22 and 37% respectively in unilateral decorticate animals, but there was no change in KD. Unilateral 6-hydroxydopamine lesions of the medial forebrain bundle caused no change in striatal [3H]spiperone binding sites or KD value, but produced a 27% increase in [3H]sulpiride binding sites with no change in KD. These data support the hypothesis of D-2 receptors located on cortico-striate glutamate fibres, but also indicate the presence of both D-1 and D-2 receptors on the cell bodies of striatal neurons.

Physiological characteristics of tremor after chronic lithium therapy

Twenty-three patients taking lithium carbonate alone in therapeutic dosage for a mean period of 43 months (range 6--108 months) and 23 control subjects matched for age and sex had the frequency and amplitude of postural tremor measured and extrapyramidal symptoms assessed by standard techniques. Patients on lithium had a significantly lower peak frequency of tremor than control subjects (P less than 0.05) and significantly greater extrapyramidal symptoms (P less than 0.01), indicating that tremor appearing after chronic lithium therapy is likely to be an extrapyramidal symptom. Such symptoms are common long-term adverse effects of lithium carbonate.

Detailed analysis of the effects of apomorphine and d-amphetamine on spontaneous locomotor behaviour of rats as measured in a TV-based, automated open-field system

Rat open field behaviour was measured in a TV-based, automated system. Habituation was evident in saline-treated rats. Most variables measured declined over a 10 min period. Apomorphine affected rat open-field behaviour bimodally, i.e. low doses of apomorphine (0.02-0.08 mg/kg, s.c.) decreased most aspects of rat open-field behaviour, whereas at higher doses (0.2 and 0.5 mg/kg, s.c.) various aspects of open-field behaviour were stimulated. Rearing and average speed, however, were monotonically depressed. Amphetamine (1 and 2 mg/kg) stimulated most aspects of rats open-field behaviour, including rearing. Speed was not affected by amphetamine. Habituation was more pronounced after low doses of apomorphine than after saline treatment and was absent after high doses of apomorphine and after amphetamine. The results represent a detailed analysis of apomorphine and amphetamine effects on rat open-field behaviour and show that the distinct components of this behaviour are affected differentially.

Effects of dopamine on cyclic AMP concentration in the anterior pituitary gland in vitro

Effects of different concentrations of dopamine on the cyclic AMP concentration in the anterior pituitary gland were investigated in vitro. Low concentrations of dopamine (10(-9)--10(-8) mol/l) were found to decrease, whereas the high concentration (10(-5) mol/l) increased the cyclic AMP concentration in pituitaries collected from ovariectomized and estradiol-treated females. In contrast, dopamine had no effect on the anterior pituitary cAMP concentration when pituitaries were collected from ovariectomized rats which had not received estrogen replacement. These data show that the action of dopamine on the anterior pituitary cAMP largely depends on the dopamine concentration and the hormonal state of animals.

[3H]Spiperone binding sites in brain: autoradiographic localization of multiple receptors

[3H]Spiperone ([3H]SP) binding sites were localized by light microscopic autoradiography, after in vitro labeling. The kinetic and pharmacological characteristics of these binding sites were studied in slide-mounted sections of rat forebrain, and optimal labeling conditions were defined. Autoradiograms were obtained by apposing emulsion-coated coverslips to labeled sections. Differential drug sensitivity allowed the selective displacement of [3H]SP from dopamine receptors by ADTN, from serotonin receptors by cinanserin, from both by haloperidol and from unique spiperone sites by unlabeled spiperone. The various sites presented a differential anatomical localization. For example, only dopaminergic sites were found in the glomerular layer of the olfactory bulb; only serotonergic sites were found in lamina IV of the neocortex, and a high concentration of unique spiperone sites was found in parts of the hippocampus.

Chronic lead treatment induces in rat a specific and differential effect on dopamine receptors in different brain areas

There is now evidence that two classes of dopaminergic receptors are present in CNS of the rat: D1, associated, and D2, not associated with adenylate cyclase activity. Drugs which interact specifically with D2 receptor are more capable of antagonizing the hyperkinetic behavior induced by lead exposure in rat. They also have a beneficial effect in children with hyperkinetic disorders. We found that the dose (-)sulpiride which causes sedation is lower in lead intoxicated animals than in controls. On the contrary, haloperidol produces sedation with the same potency in lead-treated and in control rats. The reported behavioral effects were found to be correlated with biochemical changes. In fact, in lead exposed rats D2 receptors, measured by (-)-[3H]sulpiride stereospecific binding, are altered, while D1 receptors seem not to be affected. The alterations are different according to the area examined: D2 receptor function is increased in the striatum and decreased in the nucleus accumbens. The impairment of D2 receptor might explain the better capacity of substituted benzamides to improve the hyperkinetic behavior observed in lead exposed rats.

Binding of 3H-ADTN, a dopamine agonist, to membranes of the bovine retina

The binding of 3H-ADTN, a potent dopamine receptor agonist, to crude membrane preparations of bovine retina was studied, using a filtration method to isolate membrane-bound ligand. Specific binding was found to be saturable and occurred at a single binding site with an affinity constant of 7.3 nM. Binding was sodium-independent, slightly enhanced by Triton X-100 treatment, but drastically reduced by both trypsin and sodium laurylsulphate. The binding sites demonstrated a high degree of pharmacological specificity, with dopamine, apomorphine, and epinine being potent displacers of 3H-ADTN. A higher degree of 3H-ADTN binding was associated with subcellular fractions enriched with conventional synaptosomes rather than fractions enriched with photoreceptor synaptosomes.

Chemical modification of carotid body chemoreception by sulfhydryls

Sulfhydryl reagents cause striking augmentation of the chemoreceptor responses of the carotid body to hypoxia. This indicates that a cellular plasma membrane protein with a reactive sulfhydryl group is a constituent part of the chemoreceptor architecture and provides a means of identification, localization, and isolation of the protein.

Kainic acid lesions dissociate [3H] spiperone and [3H]cis-flupenthixol binding sites in rat striatum

The effects of striatal kainic acid lesions on [3H] cis-flupenthixol ([3H]FPT) and [3H]spiperone (3H-SPIP) binding to dopamine (DA) receptors in control and lesioned striata were examined. Significant reductions in both binding parameters were observed, [3H] FPT binding was depleted to a greater extent than [3H] SPIP binding. Reductions in both [3H] FPT and [3H] SPIP binding were significantly correlated with reductions in glutamic acid decarboxylase activity. After complete loss of GAD activity, 30-40% of [3H] SPIP binding sites remained in the lesioned striata, whereas all [3H] FPT binding sites were destroyed. The results are discussed in relation to the presence of distinct types of DA receptors in rat striatum, and ligand binding to these receptors.

Presence of a particular subpopulation of dopamine receptors within the septal nuclei: a behavioural study on cats

The behavioural effects of intraseptal administration of dopaminergic drugs (apomorphine, haloperidol, (3,4-dihydroxy-phenylamino)-2-imidazoline (DPI), ergometrine and dopamine) and alpha-noradrenergic drugs (oxymetazoline, noradrenaline and phentolamine) were analysed in cats pretreated with morphine (5 mg/kg, i.p.). Changes in frequencies of stereotyped locomotor patterns were used for statistical evaluation of drug-induced effects. Taking advantage of the specificity of the drugs mentioned, a distinction could be made between effects mediated via excitation-mediating dopamine (DAe), inhibition-mediating dopamine (DAi) and alpha-noradrenaline (alpha-NA) receptors. Intraseptal injection of the DAi agonist DPI resulted in a decrease in the frequency of stereotyped locomotor patterns. This effect was dose-dependent and mimicked by that of intraseptally applied dopamine but not of any of the other drugs. Moreover, intraseptal injection of the DAi antagonist ergometrine inhibited the effect of DPI. The DAe agonist apomorphine as well as the DAe antagonist haloperidol remained ineffective when applied in low doses. The alpha-NA antagonist phentolamine and a rather high dose of haloperidol produced a slight but significant increase in the frequency of locomotor patterns; intraseptally applied oxymetazoline counteracted the phentolamine-induced effect. It is concluded that the septal nuclei of cats contain functionally active, alpha-NA receptors as well as functionally active, dopamine (DA) receptors having pharmacological properties identical to those of DA receptors present within the mesolimbic structures such as the nucleus accumbens: the so-called inhibition-mediating DAi receptors.

Biochemical genetics of neurotransmitter enzymes and receptors: relationships to schizophrenia and other major psychiatric disorders

Genetic control of catecholamine biosynthetic enzymes and dopamine receptors is described. The steady-state levels of each of the catecholamine biosynthetic enzymes in the adrenal is regulated by a single genetic locus. The entire biosynthetic pathway gives the appearance of concerted inheritance under the control of a single locus. Mesolimbic and nigrostriatal dopamine receptors are also genetically regulated. Preliminary evidence suggests that agonist binding sites differ from antagonist sites in both brain regions, and that the genetic controls, which are expressed on receptor site number, are independent in the two brain regions.

Neurotransmitter-receptor binding in various brain regions in ethanol-dependent rats

Since chronic ethanol administration has been demonstrated to induce a number of alterations in neurotransmitter utilization, the possibility was investigated that the receptors, on which these transmitters act, are altered because of a modified synaptic input. Male Sprague-Dawley rats were rendered physically-dependent on ethanol by the oral administration of 9-13 g/kg of ethanol each day over a 4 day period. The binding of radioligands specific for alpha-adrenergic, beta-adrenergic, dopaminergic, serotonergic, muscarinic cholinergic, and GABAergic receptors was assessed at various intervals after withdrawal in several areas of the brain. No alteration in receptor binding was observed at any point under the conditions studied. The data suggest that the signs of an ethanol withdrawal syndrome are not mediated through changes in the ability of neurotransmitters to interact with their receptors.

Genotypic influences on striatal dopaminergic regulation in mice

Genotypic influences on dopaminergic-induced behaviors and striatal dopaminergic receptors were evaluated in CBA/J, C57BL/6J and BALB/cJ male mice. CBA/J mice were less behaviorally sensitive to apomorphine (stereotypic behavior) but more sensitive to haloperidol (catalepsy) than C57BL/6J and BALB/cJ mice. Striatal dopaminergic receptors, assayed by binding of [3H]spiroperidol (antagonist) and [3H]ADTN (agonist), were 50% fewer in CBA/J compared to BALB/cJ mice; C57BL/6J mice had low to intermediate numbers of receptors. Striatal dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) concentrations were similar in all strains. However, a 20% higher DOPAC/dopamine ratio in CBA/J mice suggests greater dopamine turnover. Median eminence dopamine was similar in all strains, but norepinephrine was 30% higher in BALB/cJ mice. CBA/J mice failed to show antagonist-induced supersensitivity-type responses to chronic haloperidol treatment: enhanced stereotypic response to apomorphine and a 30% increase of dopaminergic receptors occurred in C57BL/6J and BALB/cJ mice, but not in CBA/J mice. These data suggest that CBA/J mice either cannot respond to chronic haloperidol treatment or have an elevated threshold for induction of supersensitivity response. Chronic treatment with the dopamine agonist bromocriptine (7d) depressed apomorphine-induced stereotypic behavior in C57BL/6J mice and eliminated stereotypy in BALB/cJ mice, but caused no change in stereotypic behavior in CBA/J mice. Dopaminergic receptors were 15% lower after bromocriptine treatment in all strains. These results suggest that some striatal dopaminergic functions are impaired in CBA/J mice relative to BALB/cJ and C57BL/6J mice. The impaired haloperidol-induced supersensitivity responses in the CBA/J mouse may be a useful model for analyzing similar impairments of supersensitivity responses in old rodents.

Sulpiride and the role of dopaminergic receptor blockade in the antipsychotic activity of neuroleptics

It is now generally recognized that dopamine receptors exist in the CNS as different subtypes: D1 receptors, associated with adenylyl cyclase activity, and D2 receptor, uncoupled to a cyclic AMP generating system. In order to understand the role of D1 and D2 receptors in the antipsychotic action of neuroleptics, we have performed subchronic treatment with haloperidol, a drug which acts on D1 receptors, and sulpiride, a selective antagonist to D2 receptors. Long-term treatment with haloperidol does not induce significant supersensitivity of the D2 receptors. In fact under these conditions 3H-(-)-sulpiride binding, which is a marker of D2 receptor function, does not increase in rat striatum, while the long-term administration of sulpiride itself produces supersensitivity of D2 receptors. Moreover, sulpiride does not induce supersensitivity of the D1 receptors, characterized by 3H-spiroperidol binding. These data suggest that both types of dopamine receptors may be involved in the clinical antipsychotic effects of neuroleptics. Unilateral lesion of the nigrostriatal dopaminergic pathway produces an increase of striatal dopaminergic receptors, measured either by 3H-spiroperidol and 3H-(-)-sulpiride binding. These findings suggest that D1 and D2 receptors are present in postsynaptic membranes while it is still not known whether they exist in the same cellular elements.

Clozapine inhibition of metenkephalin binding to synaptosome-enriched fractions of rat whole brain and hippocampus

Clozapine has been found to inhibit the binding of [3H]met-enkephalin to synaptosome-enriched fractions prepared from rat whole brain and hippocampus in a Tris-buffered media without added ions. The IC50 value for hippocampus is 28.5 microM. The inhibition constant for whole brain (41.0 microM) was found to be slightly larger than the corresponding value for chlorpromazine, which was measured under similar experimental conditions.

Kainate lesion dissociates striatal dopamine receptor radioligand binding sites

Kainic acid lesion of rat striata reduces the specific dopamine receptor binding of the butyrophenone antagonist [3H]spiperone and the butyrophenone-like antagonist [3H]domperidone by 56% and 59% respectively. Significantly greater decreases in binding were observed with the agonist [3H]N-propylnorapomorphine (NPA) and the antagonist [3H]flupentixol which showed 79% and 73% losses of high affinity binding respectively. These data indicate that, in part, [3H]spiperone and [3H]domperidone label distinct dopamine receptors with different neuronal localizations from those labeled by [3H]flupentixol and [3H]NPA. Our data is consistent with the hypothesis that [3H]flupentixol and [3H]NPA bind preferentially to adenylate cyclase-linked dopamine (D1) receptors.

Neurochemical effects of some ergot derivatives: a basis for their antiparkinson actions

Bromocriptine and the two ergoline derivatives, CQ 32-084 and CM 29-712, exert dopamine-like effects in experimental models and have been shown to possess antiparkinsonian activity. Biochemical investigations indicate that they differ in their specificity towards the different dopamine receptor types and, in addition, interact with other neurotransmitter receptors. Bromocriptine appears to be a potent agonist at D2-receptors. Furthermore, it blocks adenylate cyclase coupled serotonin receptors and antagonizes central alpha-adrenergic receptors. The two ergoline derivatives are multiple agonists. CQ 32-084 stimulates both D1- and D2-, and CM 29-712 only D1-receptors. In addition, both compounds stimulate adenylate cyclase coupled serotonin receptors and antagonize central alpha-adrenergic receptors.

A theoretical conformational study of substituted O-anisamides as models of a class of dopamine antagonists

The quantum mechanical PCILO method has been used to investigate the conformational behaviour of N-(2-aminoethyl)- and N-(2-dimethylaminoethyl)-o-anisamide, two model molecules of substituted benzamides. The molecules are shown to have only limited conformational freedom due to the presence of two intramolecular hydrogen bonds acting as conformational locks. The molecules in their preferred conformation are characterized by a distance between the centre of the aromatic ring and the nitrogen atom of almost 6 A, i.e. almost 1 A longer than in the fully extended dopamine conformers. Some implications at the receptor level of this topographical dissimilarity are discussed.

Evidence for an inhibitory presynaptic component of neuroleptic drug action

1 The action of five neuroleptic drugs (haloperidol, cis-flupenthixol, chlorpromazine, fluphenazine and thioridazine) was studied on the synthesis and release of dopamine from rat striatal synaptosomes. 2. In vitro application of the drugs induced an inhibition of synthesis of [14C]-dopamine from L-[U-14C]-tyrosine and a decrease in the tissue content of [14-C]-dopamine, with IC50 values for the latter effect ranging from 3.6 x 10(-7) to 5.9 x 10(-5) M. The rank of their potency was similar to the order of their clinical effectiveness: haloperidol greater than fluphenazine greater than cis-flupenthixol greater than chlorpromazine greater than thioridazine. Trans flupenthixol was without effect up to a concentration of 10(-4) M. 3 The tissue level and release of GABA were not affected by concentration of the neuroleptics up to 10(-4) M. 4 When the neuroleptics were administered in vivo, changes were also detected in the synthesis and release of [14C-]-dopamine from subsequently prepared synaptosomes. A marked inhibition of the K+-induced increase in [14C]-dopamine synthesis was seen following a dose of 2 mg/kg cis-flupenthixol and haloperidol. At this concentration, haloperidol also increased the control release of [14C]-dopamine and reduced the K+-induced increase in release of [14C]-dopamine. 5 Cis-flupenthixol at a dose of 20 mg/kg reduced the K+-induced release of [14C]-dopamine by 48% and to a lesser extent, that of gamma-aminobutyric acid (GABA, 25%). 6 An inhibitory mode of action is proposed for neuroleptics mediated through a presynaptic mechanism.

Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides

Dopamine receptors have been characterized by the use of radiolabelled dopamine agonists and antagonists. Using ibotenic acid induced lesions of the striatum, evidence was obtained that 3H-N-propylnorapomorphine (3H-NPA) binding sites and 3H-bromocriptine binding sites are located both on intrastriatal nerve cells and on extrinsic nerve terminals probably mainly originating in the cerebral cortex. Development of dopamine receptor supersensitivity as evaluated in 6-hydroxydopamine lesioned rats was associated with an 50% increase in the number of 3H-NPA binding sites in the striatum. Furthermore, one year following the 6-hydroxydopamine induced lesion of the dopamine pathways two binding sites for 3H-NPA could be demonstrated in the striatum. However, at this time interval the total number of 3H-NPA binding sites was not increased. The functional significance of these two binding sites for 3H-NPA in the striatum is unknown, but they are probably coupled to the biological effector in view of the marked behavioural supersensitivity demonstrated in these old animals. The dopamine receptor agonists and especially the dopaminergic ergot derivatives have been characterized by studying their affinities for 3H-bromocriptine, 3H-spiperone, 3H-ADTN and 3H-NPA binding sites in vitro. It is suggested that the Ki ratios for agonist and antagonist radioligands may be one useful way to characterize the agonist-antagonist character of the drug. Another important method is to study the effects of dopamine receptor agonists on the specific in vivo binding of 3H-spiperone and 3H-NPA. The correlation analysis of DA agonist affinities for the four radioligands of DA receptors used in the present study give evidence for the existence of at least 3 types of DA receptors. Actions of dopaminergic ergot drugs have been evaluated at supersensitive dopamine receptors. The findings suggest that the shift to the left of the threshold dose to activate supersensitive dopamine receptors could be due to a lowering of the stereoselectivity of agonist interaction at the dopamine agonist sites of supersensitive dopamine receptors. Such a change may explain the highly preferential action of CF 25-397 at supersensitive dopamine receptors, since its affinity for 3H-NPA binding sites was not increased in the present experiments. In agreement with previous work, evidence have also been presented that prolonged treatment with a potent dopaminergic drug, pergolide, can produce a down regulation of normal dopamine receptors by reducing the density of such receptors. Evidence has also been presented that CCK-8 and the desulphated CCK-8 (10(-6) M) can in vitro reduce the number of 3H-NPA binding sites in the striatum. These results indicate that cholecystokinin peptides via activation of cholecystokinin receptors can regulate the movements of the 3H-NPA binding sites across the plane of the membrane in such a way as to make them less available to the external surface of the membrane...

Characterization of the dopamine stimulated adenylate cyclase in the pedal ganglia of Mytilus edulis: interactions with etorphine, beta-endorphin, DALA, and methionine enkephalin

The dopamine-stimulated adenylate cyclase activity was studied both in vivo and in vitro in the central nervous system of the bivalve mollusc Mytilus edulis. Dopamine, epinine, and apomorphine stimulated the enzyme system. Fluphenazine, haloperidol, chlorpromaxine, and to a lesser extent BOL inhibited the dopamine-stimulated adenylate cyclase. Etorphine, beta-endorphine, DALA, and methionine enkephalin depressed cyclic AMP levels. This phenomena was naloxone reversible. In addition, the opioids inhibited the stimulation of adenylate cyclase by dopamine. This phenomena was also naloxone reversible. The study demonstrates an interaction among dopamine, the opioids, and cyclic AMP.

Sequelae of 6 months continuous administration of cis(Z)-and trans(E)-flupenthixol in the rat

Rats were treated continuously with cis(Z)- or trans (E)-flupenthixol via drinking water for 6 months. Stereotypy responses to 0.15 mg/kg apomorphine (APOM) were enduringly, and stereospecifically, antagonised by cis (Z)-flupenthixol at either 0.5-1.0 or 1.4-3.0 mg/kg per day. Responses to 1.0 mg/kg APOM were antagonised after 5 days but enhanced after 6 months on cis (Z)-flupentixol (1.4-3.0 mg/kg per day). Distinct dopamine-dependent processes may be differentially sensitive to adaptation during extended neuroleptic treatment.

Effects of estrogens on the responses of caudate neurons to microiontophoretically applied dopamine

The electrical activity of caudate neurons and their response to iontophoretically applied dopamine (DA) were tested at different time intervals before and after i.m. injection of estradiol benzoate in rats ovariectomized one week previously. One hundred and three neurons were recorded before estradiol injection and, of these, 25% were spontaneously active and 75% were driven by glutamate. The firing activity of the majority (86%) of the neurons was inhibited on application of DA. At 2--6 after the estradiol injections, the proportion of spontaneously active neurons was elevated to 87% and their firing rate was dramatically increased. Concomitantly, the proportion of cells affected by DA decreased to 39%; moreover, the majority of cells responsive to DA was now excited following it. We conclude that estrogens are able to influence the global activity of caudate neurons and to reverse their sensitivity to DA. This action may be partly mediated by the pituitary since it was not observed in ovariectomized rats which were also hypophysectomized.

Dopaminergic mechanisms in the teleost retina. I. Dopamine-sensitive adenylate cyclase in homogenates of carp retina; effects of agonists, antagonists, and ergots

A specific dopamine-sensitive adenylate cyclase has been identified in homogenates of the teleost (carp) retina. Maximal stimulation by 100 microM-dopamine resulted in a 5--10-fold increase in adenylate cyclase activity with half-maximal stimulation occurring at a concentration of 1 microM. l-Noradrenaline and l-adrenaline were some 10 times less potent than dopamine whilst the alpha- and beta-adrenoreceptor agonists, l-phenylephrine and dl-isoprenaline were inactive. Apomorphine elicited a partial stimulation of adenylate cyclase activity whilst various ergot alkaloids produced mixed agonist/antagonist responses. Dopamine-stimulated adenylate cyclase activity was potently antagonised by various neuroleptic drugs including fluphenazine, alpha-flupenthixol and alpha-piflutixol, and to a lesser extent by the butyrophenone derivatives haloperidol and spiperone. The benzamide derivatives, metoclopramide and sulpiride, together with the alpha- and beta-adrenoreceptor blocking agents, phentolamine and propranolol respectively were essentially inactive at blocking dopamine-stimulated adenylate cyclase activity. These data suggest the presence of a highly specific dopamine-sensitive adenylate cyclase in homogenates of teleost retina possessing similar pharmacological properties to the dopamine-sensitive adenylate cyclase observed in the mammalian central nervous system.

Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity

A new benzamide, cis-N-(1-benzyl-2-methylpyrrolidin - 3 - yl) - 5 - chloro - 2 - methoxy - 4 - methylaminobenzamide (YM-09151-2) exhibited more potent and longer-lasting inhibitory effects on apomorphine-induced behaviours (stereotyped behaviour, emesis and hypothermia), and methamphetamine-induced stereotyped behaviour, conditioned avoidance response and open field behaviour, conditioned avoidance response and open field behaviour than either structurally similar benzamides (YM-0850 and sulpiride) or classical neuroleptics [chlorpromazine (CPZ) and haloperidol(HPD)]. Such inhibitory effects of YM-09151-2 relative to cataleptogenicity were greater than those of CPz and HPD. In contrast, sulpiride elicited few of the neuroleptic effects described above. YM-09151-2, a potent inhibitor for dopamine-sensitive adenylate cyclase (Ki: 3.0 nM) reduced, in a selective manner, the binding of [3H]dopamine to the dopamine D1 receptor (Ki:4.8 nm) associated with adenylate cyclase rather than to the dopamine D2 receptor (Ki: 0.98 microM) independent of adenylate cyclase. Sulpiride, on the contrary, inhibited only the binding to the dopamine D2 receptor, CPZ and HPD antagonized [3H]dopamine nonselectively at the two distinct dopaminergic receptors. These results suggest that YM-09151-2 is a potent and long-lasting neuroleptic with a highly selective blocking action on the dopamine D1 receptor.

Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain

Certain neuroleptic drugs, such as spiperone and (+) butaclamol, can discriminate between two populations of [3H]5-hydroxytryptamine ([3H]5-HT) binding sites in rat brain. The butyrophenone neuroleptic spiperone shows the greatest selectivity for these two binding sites, having at least a 3000-fold difference between its dissociation constants (2-12 nM versus 35,000 nM) for the high- and low-affinity sites, respectively. Inhibition of [3H]5-HT binding by spiperone in rat frontal cortex and corpus striatum yields distinctly biphasic inhibition curves with Hill slopes significantly less than unity. Results from nonlinear regression analysis of these inhibition studies were consistent with a two-site model in each brain region. In the frontal cortex the high-affinity neuroleptic sites comprised about 60% of the total [3H]5-HT binding sites whereas in the corpus striatum they accounted for only 20% of the sites. Furthermore, saturation studies of [3H]5-HT binding assayed in the absence or presence of 1 microM-spiperone (a concentration that completely blocks the high-affinity site while having minimal activity at the low-affinity site) reveal a parallel shift in the Scatchard plot with no change in the dissociation constant of [3H]5-HT, but a significant decrease (64% in frontal cortex or 28% in corpus striatum) in the number of specific binding sites. These observations are consistent with the existence of at least two populations of [3H]5-HT binding sites having a differential regional distribution in rat brain.

Differential reversal of various dopamine antagonists by anticholinergics in Sidman avoidance: possible relationship to adrenergic blockade

Various dopamine receptor antagonists have divergent clinical and neurochemical properties. The relative ability of anticholinergics (benztropine and scopolamine) to reverse these drugs was assessed in squirrel monkeys and rats performing a Sidman avoidance task. In monkeys, benztropine markedly attenuated the effects of oxiperomide, metoclopramide, halopemide, tiapride and mezilamine as well as haloperidol. Chlorpromazine and fluphenazine were antagonized to a moderate extent; thioridazine and perlapine were not antagonized; and clozapine was actually potentiated by benztropine. In the rat, benztropine antagonized haloperidol strongly but reversed fluphenazine, thioridazine or clozapine only weakly or not at all. The overall effects of scopolamine in both species were similar to those of benztropine. The dopamine receptor antagonists that were most completely reversed by benztropine were found to inhibit 3H-spiroperidol more strongly than 3H-WB-4101 binding in calf caudate, while the reverse was true for drugs that were antagonized only moderately or not at all by benztropine. These results support a previous suggestion that anticholinergic reversal is less marked against dopamine antagonists with alpha-adrenergic blocking properties. Benztropine reversal of experimental dopamine receptor antagonists in the squirrel monkey Sidman avoidance test may contribute to their preclinical characterization.